Archive - February 2022
Orphazyme Provides Update for Planned NDA Resubmission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C in the United States
U.S. Food and Drug Administration (FDA) Accepts Mirati Therapeutics’ New Drug Application for Adagrasib as Treatment of Previously Treated KRASG12C-Mutated Non-Small Cell Lung Cancer
Ivermectin Not Effective Against Severe COVID-19, But Doctor Group Still Recommends Drug
Global Blood Therapeutics’ treatment for patients with sickle cell disease approved in Europe
Sandoz launches generic oncology treatment in Europe
Data day: Trial results deliver hope for prostate cancer patients
All trades: Syncona announces sale of portfolio company to Novartis
COVID: WHO Recommends Two New Treatments – Here’s How They Work